OneSource Pharma Q3 Collapse: Revenue Down 26%, PAT Turns Loss
Overview
OneSource Specialty Pharma Limited reported a challenging Q3FY26, with revenue plummeting 26% YoY to ₹2,903 million and EBITDA crashing 88% YoY to ₹173 million. EBITDA margins compressed to 6%. Adjusted PAT swung to a loss of ₹472 million from a profit last year. The company clarified its FY28 guidance is in US dollars ($400M-$500M revenue, ~40% EBITDA margin), citing demand and order book strength as key drivers for recovery.
Stocks Mentioned
📉 The Financial Deep Dive
OneSource Specialty Pharma Limited has unveiled a stark quarterly performance for the period ended December 31, 2025 (Q3FY26), marked by significant Year-on-Year (YoY) declines across key financial metrics. Total revenue for the quarter stood at ₹2,903 million, a considerable 26% decrease from the previous year's ₹3,922 million (Q3FY25).
The company's operational profitability suffered even more acutely. EBITDA plummeted by 88% YoY to ₹173 million from ₹1,419 million in Q3FY25. This led to a severe compression in EBITDA margins, which fell to 6% in Q3FY26, down drastically from 36% in the prior year's quarter and also lower than the 28% recorded in Q2FY26. The management attributed this margin squeeze primarily to lower revenue coupled with a largely fixed cost base.
Profitability after tax also took a hit. Adjusted Profit After Tax (PAT) registered a loss of ₹472 million in Q3FY26, a sharp reversal from a profit of ₹672 million in Q3FY25 and also a decline from the profit of ₹449 million in Q2FY26. Correspondingly, Adjusted Earnings Per Share (EPS) was a negative (₹4.1), a significant drop from ₹6.2 in Q3FY25. These figures exclude exceptional items and intangible amortisation related to schemes.
🚩 Risks & Outlook
The primary driver for the subdued quarterly results appears to be operational headwinds faced in the Canadian market, specifically delayed customer approvals for Semaglutide and a prolonged transition from the Master Services Agreement (MSA) to the Contractual Service Agreement (CSA) phase.
Despite the current challenges, management has reaffirmed its financial outlook for FY28. The company anticipates $400 million in organic revenue and $500 million including recently proposed acquisitions. A key target is achieving an EBITDA margin of approximately 40% for the fiscal year. Furthermore, the organic business is projected to achieve a Return on Capital Employed (ROCE) above 50% and maintain a Net-to-EBITDA ratio below 1.5x. Management expressed confidence in intact inherent demand, an upward trending order book, and strong interest in the nascent biologics segment, with a new global biosimilar player onboarded and a robust sales funnel.
Investors will need to closely monitor the company's ability to navigate the ongoing operational transitions and the pace of recovery in the coming quarters to assess the achievability of these ambitious FY28 targets. The absence of specific balance sheet, cash flow, or quantitative order book data in the release limits a comprehensive financial assessment. Additionally, a clarification addendum was issued regarding a typographical error in the currency of the FY28 guidance, which was correctly stated as US dollars ($) and not Indian Rupees (₹), underscoring the need for precision in financial disclosures.
